Edition:
United States

Novogen Ltd (NVGN.OQ)

NVGN.OQ on NASDAQ Stock Exchange Capital Market

0.87USD
19 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.87
Open
$0.91
Day's High
$0.91
Day's Low
$0.87
Volume
1,304
Avg. Vol
6,823
52-wk High
$2.43
52-wk Low
$0.86

NVGN.OQ

Chart for NVGN.OQ

About

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug... (more)

Overall

Beta: 0.07
Market Cap(Mil.): $17.30
Shares Outstanding(Mil.): 19.33
Dividend: --
Yield (%): --

Financials

  NVGN.OQ Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -0.53 -- --
ROI: -29.63 2.34 -5.89
ROE: -33.93 0.22 -5.30

BRIEF-Novogen terminates ATM-3507 preclinical development program

* Novogen terminates ATM-3507 preclinical development program

Apr 05 2017

BRIEF-Novogen says CFO Cristyn Humphreys will leave company

* Cristyn Humphreys, chief financial officer (CFO) at Novogen will leave Novogen later this month to assume a new role outside industry

Mar 09 2017

BRIEF-Novogen awarded grant for novel drug discovery

* Novogen awarded grant of up to $3mln for novel drug discovery Source text for Eikon: Further company coverage:

Feb 08 2017

More From Around the Web

Earnings vs. Estimates